To explore the impact of ECI2 on ccRCC tumor cells, we developed a cell line overexpressing ECI2. The findings indicate that overexpression of ECI2 suppresses tumor cell growth and migration and enhances ccRCC cells' sensitivity to oxaliplatin. Here, ECI2 is linked to nonpapillary renal cell carcinoma.